Story · Medicine & Biotech

David Aggen: Ongoing Phase III Trials Bring New Perspectives to First-Line mUC Treatment

1 outlet · first reported by OncoDaily on

David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Here are the phase III trials on-going for front-line mUC. Second time Tom Powles used win on (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study randomized trial
    David Aggen: Ongoing Phase III Trials Bring New Perspectives to First-Line mUC Treatment

    David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X: “Here are the phase III trials on-going for front-line mUC. Second time Tom Powles used win on

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.